drugset / Trial / NCT02491788
Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers
Phase 4
Completed
19 enrolled
VA Palo Alto Health Care System
Merck Sharp & Dohme LLC · collabStanford University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
Timeline
- Start
- 2016-02-01
- Primary completion
- 2019-08-01
- Completion
- 2019-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Suvorexant | Small molecule | 20 mg | — |